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Background 
Ozone therapy has a long history. Some studies proved that ozone therapy 
was useful in treatment of virus hepatitis. 

Objective 
To evaluate the efficacy and safety of new medical ozone therapy system 
for the treatment of chronic hepatitis B. 

Method  
One hundred eighty-nine patients with chronic hepatitis B were included in 
this open-label, phase 3 study, and randomly assigned to receive ozone 
autohemotherapy with experimental ozone generator TianYi (group 1) or 
with ozone generator Humares (group 2) or oral diammonium glycyrrhizinate 
capsules (group 3) in a 1:1:1 ratio for 12 weeks. The primary efficacy end 
point was sera HBV DNA level of less than 1×103 IU/ml or having a more 
than 2 log10 reduction in HBV DNA level at the end of 12 weeks treatment 
as compared to baseline HBV DNA level. Secondary end points included 
HBeAg seroconversion, biochemical response, and combined response. 

Results  
At the end of 12 weeks treatment, the proportion of patients reached the 
primary end point of virologic response in group 1, group 2, and group 3 
were 22.4% (13/58, 95% CI, 12.5 to 35.3), 14.7 (9/61, 95% CI, 7.0 to 26.2) 
and 3.9% (2/51, 95% CI, 0.5 to 13.5), respectively (p=0.021) in the pre-
protocol population. Virologic response occurred in more patients receiving 
ozone therapy with experimental device than patients receiving oral 
diammonium glycyrrhizinate capsules (mean difference 18.5%, 95% CI 6.3 
to 31.5, p=0.005). However, there was no statistical difference in VR12 rates 
between the treatment of medical ozone therapy system with experimental 
device (group 1) and with Humares (group 2) (mean difference 7.7%, 95% 
CI -6.5 to 22.0, p=0.282). More HBeAg seroconversion in patients treated by 
Tianyi ozone therapy system than those treated by Humares ozone therapy 
device and oral diammonium glycyrrhizinate capsules (14.8%, 5.1% and 
7.3%, respectively, P = 0.272). Higher biochemical response rate was 
observes in patients receiving ozone therapy than oral diammonium 
glycyrrhizinate capsules (31.6%, 36.7% and 24.0%, respectively, p = 0.359). 
The safety profile was similar for the three treatment groups and adverse 
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Conclusions  
Ozone therapy had superior antiviral efficacy with a similar safety profile as 
compared with oral diammonium glycyrrhizinate capsules through week 12 
treatment. Ozone therapy is also associated with normalized ALT and AST 
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